Omeros Begins Commercial Sales of Stem Cell Complication Drug Yartemlea

MT Newswires Live01-27

Omeros (OMER) said Tuesday that it has begun commercial sales of Yartemlea following initial shipments to distributors and early use by transplant centers in the US.

Financial details related to early sales were not provided.

The company said that orders were received and filled last week, and that the drug is now being given to both adult and pediatric patients with transplant-associated thrombotic microangiopathy, including those treated in hospitals and outpatient settings.

Omeros said Yartemlea received US Food and Drug Administration approval last month and is cleared for patients aged two years and older.

Omeros said an application seeking European approval for Yartemlea is under review by regulators, with a decision expected in mid-2026.

Price: 11.56, Change: +0.03, Percent Change: +0.22

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606738060?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 22:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606738060","market":"fut","top_or_hot":-1,"title":"Omeros Begins Commercial Sales of Stem Cell Complication Drug Yartemlea","media":"MT Newswires Live","content":"<html><body><p> Omeros (OMER) said Tuesday that it has begun commercial sales of Yartemlea following initial shipments to distributors and early use by transplant centers in the US.</p><p>Financial details related to early sales were not provided.</p><p>The company said that orders were received and filled last week, and that the drug is now being given to both adult and pediatric patients with transplant-associated thrombotic microangiopathy, including those treated in hospitals and outpatient settings.</p><p>Omeros said Yartemlea received US Food and Drug Administration approval last month and is cleared for patients aged two years and older.</p><p>Omeros said an application seeking European approval for Yartemlea is under review by regulators, with a decision expected in mid-2026.</p><p>Price: 11.56, Change: +0.03, Percent Change: +0.22</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Omeros Begins Commercial Sales of Stem Cell Complication Drug Yartemlea</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOmeros Begins Commercial Sales of Stem Cell Complication Drug Yartemlea\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-27 22:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Omeros (OMER) said Tuesday that it has begun commercial sales of Yartemlea following initial shipments to distributors and early use by transplant centers in the US.</p><p>Financial details related to early sales were not provided.</p><p>The company said that orders were received and filled last week, and that the drug is now being given to both adult and pediatric patients with transplant-associated thrombotic microangiopathy, including those treated in hospitals and outpatient settings.</p><p>Omeros said Yartemlea received US Food and Drug Administration approval last month and is cleared for patients aged two years and older.</p><p>Omeros said an application seeking European approval for Yartemlea is under review by regulators, with a decision expected in mid-2026.</p><p>Price: 11.56, Change: +0.03, Percent Change: +0.22</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OMER","symbol_name":"奥麦罗制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2606738060","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606738060","pubTimestamp":1769525528,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Omeros  said Tuesday that it has begun commercial sales of Yartemlea following initial shipments to distributors and early use by transplant centers in the US.Financial details related to early sales were not provided.The company said that orders were received and filled last week, and that the drug is now being given to both adult and pediatric patients with transplant-associated thrombotic microangiopathy, including those treated in hospitals and outpatient settings.Omeros said Yartemlea received US Food and Drug Administration approval last month and is cleared for patients aged two years and older.Omeros said an application seeking European approval for Yartemlea is under review by regulators, with a decision expected in mid-2026.Price: 11.56, Change: +0.03, Percent Change: +0.22","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"OMER":"奥麦罗制药"},"translate_title":"Omeros开始商业化销售干细胞并发症药物Yartemlea","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMER":1.5},"content_text":"Omeros (OMER) said Tuesday that it has begun commercial sales of Yartemlea following initial shipments to distributors and early use by transplant centers in the US.Financial details related to early sales were not provided.The company said that orders were received and filled last week, and that the drug is now being given to both adult and pediatric patients with transplant-associated thrombotic microangiopathy, including those treated in hospitals and outpatient settings.Omeros said Yartemlea received US Food and Drug Administration approval last month and is cleared for patients aged two years and older.Omeros said an application seeking European approval for Yartemlea is under review by regulators, with a decision expected in mid-2026.Price: 11.56, Change: +0.03, Percent Change: +0.22","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606738060","isCrawlerRequest":true}